Higher dose tested for psoriasis patients who weigh more

NCT ID NCT04306315

Completed Disease control Sponsor: LEO Pharma Source: ClinicalTrials.gov ↗

Summary

This study tested if a higher, adjustable dose of the psoriasis medication brodalumab works better for people who weigh over 120 kg. It compared this adjusted dose to the standard dose over 52 weeks. The goal was to see if the higher dose could improve skin clearance and quality of life for this specific group of patients.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

LEO Pharma Investigational Site

Brussels, 1200, Belgium
LEO Pharma Investigational Site

Ham-sur-Heure-Nalinnes, 6120, Belgium
LEO Pharma Investigational Site

Leuven, 3000, Belgium
LEO Pharma Investigational Site

Liège, B-4000, Belgium
LEO Pharma Investigational Site

Kutná Hora, 284 01, Czechia
LEO Pharma Investigational Site

Nový Jičín, 741 01, Czechia
LEO Pharma Investigational Site

Plzen-Bory, 305 99, Czechia
LEO Pharma Investigational Site

Amiens, Somme, 80054, France
LEO Pharma Investigational Site

Saint-Priest-en-Jarez, 42270, France
LEO Pharma Investigational Site

Toulouse, 31059, France
LEO Pharma Investigational Site

Valence, 13616, France
LEO Pharma Investigational Site

Langenau, Baden-Wurttemberg, 89129, Germany
LEO Pharma Investigational Site

Limburg an der Lahn, Hesse, 56242, Germany
LEO Pharma Investigational Site

Wiesbaden, Hesse, 65189, Germany
LEO Pharma Investigational Site

Lohne, Lower Saxony, 49393, Germany
LEO Pharma Investigational Site

Mainz, Rhineland-Palatinate, 55128, Germany
LEO Pharma Investigational Site

Kiel, Schleswig-Holstein, 24105, Germany
LEO Pharma Investigational Site

Berlin, State of Berlin, 10117, Germany
LEO Pharma Investigational Site

Bad Bentheim, 48455, Germany
LEO Pharma Investigational Site

Bielefeld, 33647, Germany
LEO Pharma Investigational Site

Hamburg, 20246, Germany
LEO Pharma Investigational Site

Memmingen, 87700, Germany
LEO Pharma Investigational Site

Münster, 48149, Germany
LEO Pharma Investigational Site

Oldenburg, 26133, Germany
LEO Pharma Investigational Site

Osnabrück, 49074, Germany
LEO Pharma Investigational Site

Heraklion, Crete, 711 10, Greece
LEO Pharma Investigational Site

Athens, 115 25, Greece
LEO Pharma Investigational Site

Athens, 16121, Greece
LEO Pharma Investigational Site

Piraeus, 185 36, Greece
LEO Pharma Investigational Site

Thessaloniki, 546 43, Greece
LEO Pharma Investigational Site

Thessaloniki, 54643, Greece
LEO Pharma Investigational Site

Thessaloniki, 56403, Greece
LEO Pharma Investigational Site

Debrecen, 4032, Hungary
LEO Pharma Investigational Site

Orosháza, 5900, Hungary
LEO Pharma Investigational Site

Szolnok, 5000, Hungary
LEO Pharma Investigational Site

Veszprém, 8200, Hungary
LEO Pharma Investigational Site

Ancona, 60020, Italy
LEO Pharma Investigational Site

Bologna, 40138, Italy
LEO Pharma Investigational Site

Brescia, 25123, Italy
LEO Pharma Investigational Site

Coppito, 67100, Italy
LEO Pharma Investigational Site

Modena, 41124, Italy
LEO Pharma Investigational Site

Naples, 80131, Italy
LEO Pharma Investigational Site

Parma, 43126, Italy
LEO Pharma Investigational Site

Pavia, 27100, Italy
LEO Pharma Investigational Site

Roma, 00133, Italy
LEO Pharma Investigational Site

Roma, 00168, Italy
LEO Pharma Investigational Site

Rozzano, 20089, Italy
LEO Pharma Investigational Site

Beek, 6191 JW, Netherlands
LEO Pharma Investigational Site

Iwonicz-Zdrój, 38-440, Poland
LEO Pharma Investigational Site

Lodz, 90-242, Poland
LEO Pharma Investigational Site

Lodz, 90-436, Poland
LEO Pharma Investigational Site

Lublin, 20-362, Poland
LEO Pharma Investigational Site

Lublin, 20-412, Poland
LEO Pharma Investigational Site

Poznan, 60-529, Poland
LEO Pharma Investigational Site

Skierniewice, 96-100, Poland
LEO Pharma Investigational Site

Warsaw, 02-482, Poland
LEO Pharma Investigational Site

Warsaw, 02-758, Poland
LEO Pharma Investigational Site

Warsaw, 02-801, Poland
LEO Pharma Investigational Site

Wroclaw, 50-566, Poland
LEO Pharma Investigational Site

Wroclaw, 51-318, Poland
LEO Pharma Investigational Site

Wroclaw, 52-416, Poland
LEO Pharma Investigational Site

Alicante, 03010, Spain
LEO Pharma Investigational Site

Badalona, 08916, Spain
LEO Pharma Investigational Site

Barcelona, 08025, Spain
LEO Pharma Investigational Site

Barcelona, 08035, Spain
LEO Pharma Investigational Site

Granada, 18014, Spain
LEO Pharma Investigational Site

Manises, 46940, Spain
LEO Pharma Investigational Site

Pontevedra, 36001, Spain
LEO Pharma Investigational Site

Pozuelo de Alarcón, 28223, Spain
LEO Pharma Investigational Site

Santiago de Compostela, 15706, Spain
LEO Pharma Investigational Site

Valencia, 46014, Spain
LEO Pharma Investigational Site

Villajoyosa, 03570, Spain
LEO Pharma Investigational Site

Chorley, PR7 7NA, United Kingdom
LEO Pharma Investigational Site

Corby, NN17 2UR, United Kingdom
LEO Pharma Investigational Site

Corby, NN18 9EZ, United Kingdom
LEO Pharma Investigational Site

Coventry, CV3 4FJ, United Kingdom
LEO Pharma Investigational Site

Liverpool, L22 0LG, United Kingdom
LEO Pharma Investigational Site

London, BR5 3QG, United Kingdom
LEO Pharma Investigational Site

London, E1 2ES, United Kingdom
LEO Pharma Investigational Site

Northwood, HA6 2RN, United Kingdom
LEO Pharma Investigational Site

Shipley, BD18 35A, United Kingdom

Conditions

Explore the condition pages connected to this study.

PSORIASIS VULGARIS